These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1670546)

  • 21. Substrate-assisted antibody catalysis.
    Deng S; Bharat N; de Prada P; Landry DW
    Org Biomol Chem; 2004 Feb; 2(3):288-90. PubMed ID: 14747854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catalysis of decarboxylation by a preorganized heterogeneous microenvironment: crystal structures of abzyme 21D8.
    Hotta K; Lange H; Tantillo DJ; Houk KN; Hilvert D; Wilson IA
    J Mol Biol; 2000 Oct; 302(5):1213-25. PubMed ID: 11183784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization.
    Miyashita H; Hara T; Tanimura R; Fukuyama S; Cagnon C; Kohara A; Fujii I
    J Mol Biol; 1997 Apr; 267(5):1247-57. PubMed ID: 9150409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic analysis of the phosphonate transition-state analogue-derived catalytic and non-catalytic antibody.
    Nishi Y; Yamamoto N; Shimazaki K; Takahashi-Ando N; Kakinuma H; Jialin S; Ruzheinikov SN; Muranova TA; Rice DW; Kajihara Y
    J Biochem; 2007 Oct; 142(4):421-33. PubMed ID: 17981825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental determination of the absolute enantioselectivity of an antibody-catalyzed Diels-Alder reaction and theoretical explorations of the origins of stereoselectivity.
    Cannizzaro CE; Ashley JA; Janda KD; Houk KN
    J Am Chem Soc; 2003 Mar; 125(9):2489-506. PubMed ID: 12603137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analysis of the affinity maturation of antibody 48G7.
    Yang PL; Schultz PG
    J Mol Biol; 1999 Dec; 294(5):1191-201. PubMed ID: 10600377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for antibody catalysis of a disfavored ring closure reaction.
    Gruber K; Zhou B; Houk KN; Lerner RA; Shevlin CG; Wilson IA
    Biochemistry; 1999 Jun; 38(22):7062-74. PubMed ID: 10353817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution.
    Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I
    J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localization of protease activity in antibody subunits.
    Sun M; Li L; Gao QS; Paul S
    Ann N Y Acad Sci; 1995 Sep; 764():573-5. PubMed ID: 7486588
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of a high-throughput screen for protein catalysts: application to the directed evolution of antibody aldolases.
    Gildersleeve J; Varvak A; Atwell S; Evans D; Schultz PG
    Angew Chem Int Ed Engl; 2003 Dec; 42(48):5971-3. PubMed ID: 14679545
    [No Abstract]   [Full Text] [Related]  

  • 31. The interplay between binding energy and catalysis in the evolution of a catalytic antibody.
    Ulrich HD; Mundorff E; Santarsiero BD; Driggers EM; Stevens RC; Schultz PG
    Nature; 1997 Sep; 389(6648):271-5. PubMed ID: 9305839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catalytic antibodies: evolution of protein function in real time.
    Lerner RA; Janda KD
    EXS; 1995; 73():121-38. PubMed ID: 7579971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alchemy, enzymes, and the blind-watchmaker.
    Barbas CF; List B
    Nat Biotechnol; 1998 May; 16(5):423-4. PubMed ID: 9592389
    [No Abstract]   [Full Text] [Related]  

  • 34. Induction of covalent binding antibodies.
    Armentano F; Knight T; Makker S; Tramontano A
    Immunol Lett; 2006 Feb; 103(1):51-7. PubMed ID: 16297987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonspecific medium effects versus specific group positioning in the antibody and albumin catalysis of the base-promoted ring-opening reactions of benzisoxazoles.
    Hu Y; Houk KN; Kikuchi K; Hotta K; Hilvert D
    J Am Chem Soc; 2004 Jul; 126(26):8197-205. PubMed ID: 15225061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis for a disfavored elimination reaction in catalytic antibody 1D4.
    Larsen NA; Heine A; Crane L; Cravatt BF; Lerner RA; Wilson IA
    J Mol Biol; 2001 Nov; 314(1):93-102. PubMed ID: 11724535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catalytic antibody model and mutagenesis implicate arginine in transition-state stabilization.
    Roberts VA; Stewart J; Benkovic SJ; Getzoff ED
    J Mol Biol; 1994 Jan; 235(3):1098-116. PubMed ID: 8289310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrabody construction and expression. II. A synthetic catalytic Fv fragment.
    Ohage EC; Wirtz P; Barnikow J; Steipe B
    J Mol Biol; 1999 Sep; 291(5):1129-34. PubMed ID: 10518948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transition-state stabilization as a measure of the efficiency of antibody catalysis.
    Stewart JD; Benkovic SJ
    Nature; 1995 Jun; 375(6530):388-91. PubMed ID: 7760931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleophilic proteolytic antibodies.
    Gololobov G; Tramontano A; Paul S
    Appl Biochem Biotechnol; 2000; 83(1-3):221-31; discussion 231-2, 297-313. PubMed ID: 10826962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.